表紙
市場調査レポート

バイオマーカーの世界市場 〜2020年:製品 (消耗品・サービス)・タイプ・用途 (診断・創薬・個別化医療)・適応症 (心臓血管疾患・免疫性疾患) 別

Biomarkers Market by Product (Consumables, Services), Type (Predictive, Pharmacodynamic, Safety), Application (Diagnostics, Drug Discovery, Personalized Medicine) & by Disease Indication (Cardiovascular, Immunological) - Global Forecast to 2020

発行 MarketsandMarkets 商品コード 230633
出版日 ページ情報 英文 182 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
バイオマーカーの世界市場 〜2020年:製品 (消耗品・サービス)・タイプ・用途 (診断・創薬・個別化医療)・適応症 (心臓血管疾患・免疫性疾患) 別 Biomarkers Market by Product (Consumables, Services), Type (Predictive, Pharmacodynamic, Safety), Application (Diagnostics, Drug Discovery, Personalized Medicine) & by Disease Indication (Cardiovascular, Immunological) - Global Forecast to 2020
出版日: 2015年07月17日 ページ情報: 英文 182 Pages
概要

バイオマーカー市場の成長は主に医療費の拡大や、R&Dへの投資の拡大、診断におけるバイオマーカー利用の増加、CRO数の増加、新興国での臨床試験の低コスト性、バイオマーカー研究に対する新たなイニシアチブなどによって推進されています。新興市場での高い成長の可能性や、個別化医療やコンパニオン診断の導入拡大などが参入企業に成長機会をもたらしています。

当レポートでは、世界のバイオマーカー市場について調査し、製品および市場の概要、産業構造とバリューチェーン、市場成長への各種影響因子および市場機会の分析、製品形態・バイオマーカーのタイプ・用途・適応症別の市場分析および市場成長予測、地域および主要国の動向、競合環境と市場シェア、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 市場機会
  • ライフサイクル分析:地域別

第5章 市場概要

  • イントロダクション
  • 市場区分
    • 製品別
    • タイプ別
    • 用途別
    • 適応症別
  • 市場力学
    • 成長推進因子
    • 成長阻害因子
    • 市場機会
    • 課題

第6章 バイオマーカー市場:製品別

  • イントロダクション
  • 消耗品
  • サービス
  • ソフトウェア

第7章 バイオマーカー市場:タイプ別

  • イントロダクション
  • 安全性バイオマーカー (毒性バイオマーカー)
  • 薬理バイオマーカー
    • 予測バイオマーカー
    • 代替バイオマーカー (サロゲートバイオマーカー)
    • 薬力学バイオマーカー
    • 予後バイオマーカー
  • バリデーションバイオマーカー

第8章 バイオマーカー市場:用途別

  • イントロダクション
  • 診断の開発
  • 新薬の発見・開発
  • 個別化医療
  • 疾患リスク評価
  • その他

第9章 バイオマーカー市場:適応症別

  • イントロダクション
  • 心臓血管疾患
  • 神経疾患
  • 免疫性疾患
  • その他

第10章 バイオマーカー市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
  • アジア
  • その他

第11章 競合環境

  • イントロダクション
  • 戦略的概要
  • 市場シェア分析
  • 競合状況・動向
    • 買収
    • 合意・提携・拡張・ジョイントベンチャー・協力
    • 新製品・サービスの投入
    • その他

第12章 企業プロファイル

  • イントロダクション
  • QIAGEN N.V.
  • PERKINELMER, INC.
  • MERCK & CO, INC.
  • BIO-RAD LABORATORIES, INC.
  • ENZO BIOCHEM, INC.
  • EKF DIAGNOSTICS HOLDINGS, INC.
  • MESO SCALE DIAGNOSTICS, LLC.
  • SINGULEX, INC.
  • BIOSIMS TECHNOLOGIES
  • CISBIO BIOASSAYS
  • SIGNOSIS, INC.
    • 概要
    • 財務情報
    • 製品・サービス
    • 戦略
    • 発展動向、など

第13章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BT 2120

In this report, the biomarkers market is segmented on the basis of product, type, application, disease indication, and geography. The product segments included in this report are consumables, services, software. The type segments included in this report are safety biomarkers, efficacy biomarkers, and validation biomarkers. The applications segments included in this report are diagnostics development, drug discovery and development, personalized medicine, disease risk assessment, and other applications. The disease indications segments included in this report are cancer, cardiovascular disorders, neurological disorders, immunological disorders, and other diseases.

The geographic segments included in this report are North America, Europe, Asia, and the Rest of the World (RoW).

The growth of this market is mainly driven by increasing healthcare expenditure, increase in R&D spending, increasing utility of biomarkers for diagnostics, increasing number of CROs, the low cost of clinical trials in developing countries, and new initiatives for biomarker research. The high growth potential in emerging markets and the increasing adoption of personalized medicine and companion diagnostics provides new growth opportunities to players in the biomarkers market.

A combination of bottom-up and top-down approaches were used to calculate the market sizes and growth rates of the global biomarkers market and its subsegments. Secondary information was used to identify overall revenue, geographic reach, and product portfolios of market players. Estimates of the biomarkers market segment revenues were validated through primary interviews. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates.

The report provides qualitative insights on key market shares, growth rates, and market drivers for important subsegments. It maps the market sizes and growth rates of each segment and identifies segments poised to witness rapid growth. The report includes company profiles and a competitive landscape of the biomarkers market. The company profiles include the financial performances, product portfolios, and developments of each company, whereas, the competitive landscape covers the growth strategies adopted by industry players over the last three years. The report also includes analyses of industry developments such as acquisitions, agreements, collaborations & partnerships; new product launches; and other developments.

Reasons to Buy the Report:

The report will enable both established firms and new entrants to gauge the pulse of the market and make important strategic growth decisions.

The report provides insights on the following:

  • Product Development/Innovation: Product portfolios of the top players in the biomarkers market. Detailed insights on upcoming technologies, R&D activities, and new product launches in the biomarkers market
  • Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of the leading players in the biomarkers market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various biomarkers across geographies
  • Market Diversification: Exhaustive information about new products, recent developments, and investments in the biomarkers market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED IN THE REPORT
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.3. MARKET SHARE ESTIMATION
    • 2.3.1. KEY DATA FROM SECONDARY SOURCES
    • 2.3.2. KEY DATA FROM PRIMARY SOURCES
    • 2.3.3. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. LUCRATIVE OPPORTUNITIES IN THE GLOBAL BIOMARKERS MARKET
  • 4.2. LIFE CYCLE ANALYSIS, BY REGION, 2015

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
    • 5.2.1. BY PRODUCT
    • 5.2.2. BY TYPE
    • 5.2.3. BY APPLICATION
    • 5.2.4. BY DISEASE INDICATION
  • 5.3. MARKET DYNAMICS
    • 5.3.1. DRIVERS
      • 5.3.1.1. Increasing healthcare expenditure
      • 5.3.1.2. Growth in R&D funding
      • 5.3.1.3. Increasing utility of biomarkers for diagnostic purposes
      • 5.3.1.4. Rising number of CROs and low cost for conducting clinical trials in developing countries
      • 5.3.1.5. High prevalence of cancer
      • 5.3.1.6. New initiatives for biomarker research
    • 5.3.2. RESTRAINTS
      • 5.3.2.1. High capital investment and low benefit-cost ratio
      • 5.3.2.2. Poorly suited regulatory and reimbursement systems
      • 5.3.2.3. High cost of tests
      • 5.3.2.4. Technical issues related to sample collection and storage
    • 5.3.3. OPPORTUNITIES
      • 5.3.3.1. Personalized medicine
      • 5.3.3.2. Companion diagnostics
      • 5.3.3.3. Emerging economies
    • 5.3.4. CHALLENGES
      • 5.3.4.1. Proving clinical validity and utility of biomarker-based tests

6. BIOMARKERS MARKET, BY PRODUCTS

  • 6.1. INTRODUCTION
  • 6.2. CONSUMABLES
  • 6.3. SERVICES
  • 6.4. SOFTWARE

7. BIOMARKERS MARKET, BY TYPE

  • 7.1. INTRODUCTION
  • 7.2. SAFETY BIOMARKERS
  • 7.3. EFFICACY BIOMARKERS
    • 7.3.1. PREDICTIVE BIOMARKERS
    • 7.3.2. SURROGATE BIOMARKERS
    • 7.3.3. PHARMACODYNAMIC BIOMARKERS
    • 7.3.4. PROGNOSTIC BIOMARKERS
  • 7.4. VALIDATION BIOMARKERS

8. BIOMARKERS MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. DIAGNOSTICS DEVELOPMENT
  • 8.3. DRUG DISCOVERY AND DEVELOPMENT
  • 8.4. PERSONALIZED MEDICINE
  • 8.5. DISEASE RISK ASSESSMENT
  • 8.6. OTHER APPLICATIONS

9. BIOMARKERS MARKET, BY DISEASE INDICATION

  • 9.1. INTRODUCTION
  • 9.2. CANCER
  • 9.3. CARDIOVASCULAR DISORDERS
  • 9.4. NEUROLOGICAL DISORDERS
  • 9.5. IMMUNOLOGICAL DISORDERS
  • 9.6. OTHER DISEASES

10. BIOMARKERS MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. U.S.
    • 10.2.2. CANADA
  • 10.3. EUROPE
  • 10.4. ASIA
  • 10.5. REST OF THE WORLD (ROW)

11. COMPETITIVE LANDSCAPE

  • 11.1. INTRODUCTION
  • 11.2. STRATEGIC OVERVIEW
  • 11.3. MARKET SHARE ANALYSIS, BIOMARKERS MARKET
  • 11.4. COMPETITIVE SITUATION AND TRENDS
    • 11.4.1. ACQUISITIONS
    • 11.4.2. AGREEMENTS, COLLABORATIONS, EXPANSION, JOINT VENTURES, AND PARTNERSHIPS
    • 11.4.3. NEW PRODUCT AND SERVICE LAUNCHES
    • 11.4.4. OTHER DEVELOPMENTS

12. COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 12.1. INTRODUCTION
  • 12.2. QIAGEN N.V.
  • 12.3. PERKINELMER, INC.
  • 12.4. MERCK & CO, INC.
  • 12.5. BIO-RAD LABORATORIES, INC.
  • 12.6. ENZO BIOCHEM, INC.
  • 12.7. EKF DIAGNOSTICS HOLDINGS, INC.
  • 12.8. MESO SCALE DIAGNOSTICS, LLC.
  • 12.9. SINGULEX, INC.
  • 12.10. BIOSIMS TECHNOLOGIES
  • 12.11. CISBIO BIOASSAYS
  • 12.12. SIGNOSIS, INC.

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. INSIGHTS OF INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. OTHER DEVELOPMENTS
  • 13.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.5. AVAILABLE CUSTOMIZATIONS
  • 13.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: BIOMARKERS MARKET SNAPSHOT
  • TABLE 2: INCREASING HEALTHCARE EXPENDITURE IS PROPELLING THE GROWTH OF BIOMARKERS MARKET
  • TABLE 3: POORLY SUITED REGULATORY AND REIMBURSEMENT SYSTEMS-AN ENTRY BARRIER FOR NEW ENTRANTS
  • TABLE 4: LIST OF FDA-APPROVED BIOMARKERS FOR DIFFERENT TYPES OF CANCER
  • TABLE 5: EMERGING ECONOMIES PRESENT SIGNIFICANT GROWTH OPPORTUNITIES
  • TABLE 6: PROVING THE CLINICAL VALIDITY & UTILITY OF BIOMARKER-BASED TESTS IS A MAJOR CHALLENGE FOR MARKET PLAYERS
  • TABLE 7: BIOMARKERS MARKET SIZE, BY PRODUCT, 2013-2020 ($BILLION)
  • TABLE 8: BIOMARKER CONSUMABLES MARKET, BY REGION, 2013-2020 ($BILLION)
  • TABLE 9: NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY REGION, 2013-2020 ($BILLION)
  • TABLE 10: BIOMARKER SERVICES MARKET, BY REGION, 2013-2020 ($BILLION)
  • TABLE 11: NORTH AMERICA: BIOMARKER SERVICES MARKET, BY REGION, 2013-2020 ($BILLION)
  • TABLE 12: BIOMARKER SOFTWARE MARKET, BY REGION, 2013-2020 ($BILLION)
  • TABLE 13: NORTH AMERICA: BIOMARKER SOFTWARE MARKET, BY REGION, 2013-2020 ($MILLION)
  • TABLE 14: BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION)
  • TABLE 15: SAFETY BIOMARKERS MARKET SIZE, BY REGION, 2013-2020 ($BILLION)
  • TABLE 16: NORTH AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2013-2020 ($BILLION)
  • TABLE 17: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION)
  • TABLE 18: EFFICACY BIOMARKERS MARKET SIZE, BY REGION, 2013-2020 ($BILLION)
  • TABLE 19: NORTH AMERICA: EFFICACY BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 ($BILLION)
  • TABLE 20: PREDICTIVE BIOMARKERS MARKET SIZE, BY REGION, 2013-2020 ($BILLION)
  • TABLE 21: NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)
  • TABLE 22: SURROGATE BIOMARKERS MARKET SIZE, BY REGION, 2013-2020 ($BILLION)
  • TABLE 23: NORTH AMERICA: SURROGATE BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 ($BILLION)
  • TABLE 24: PHARMACODYNAMIC BIOMARKERS MARKET SIZE, BY REGION, 2013-2020 ($BILLION)
  • TABLE 25: NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 ($BILLION)
  • TABLE 26: PROGNOSTIC BIOMARKERS MARKET SIZE, BY REGION, 2013-2020 ($BILLION)
  • TABLE 27: NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 ($BILLION)
  • TABLE 28: VALIDATION BIOMARKERS MARKET SIZE, BY REGION, 2013-2020 ($BILLION)
  • TABLE 29: NORTH AMERICA: VALIDATION BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 ($BILLION)
  • TABLE 30: BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 ($BILLION)
  • TABLE 31: DIAGNOSTICS DEVELOPMENT MARKET SIZE, BY REGION, 2013-2020 ($BILLION)
  • TABLE 32: NORTH AMERICA: DIAGNOSTICS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2013-2020 ($BILLION)
  • TABLE 33: DRUG DISCOVERY AND DEVELOPMENT MARKET SIZE, BY REGION, 2013-2020 ($BILLION)
  • TABLE 34: NORTH AMERICA: DRUG DISCOVERY AND DEVELOPMENT MARKET SIZE, BY COUNTRY, 2013-2020 ($BILLION)
  • TABLE 35: PERSONALIZED MEDICINE MARKET SIZE, BY REGION, 2013-2020 ($BILLION)
  • TABLE 36: NORTH AMERICA: PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2013-2020 ($BILLION)
  • TABLE 37: DISEASE RISK ASSESSMENT MARKET SIZE, BY REGION, 2013-2020 ($BILLION)
  • TABLE 38: NORTH AMERICA: DISEASE RISK ASSESSMENT MARKET SIZE, BY COUNTRY, 2013-2020 ($BILLION)
  • TABLE 39: BIOMARKERS MARKET SIZE FOR OTHER APPLICATIONS, BY REGION, 2013-2020 ($BILLION)
  • TABLE 40: NORTH AMERICA: BIOMARKERS MARKET SIZE FOR OTHER APPLICATIONS, BY COUNTRY, 2013-2020 ($BILLION)
  • TABLE 41: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2013-2020 ($BILLION)
  • TABLE 42: KEY CANCER BIOMARKERS IN CLINICAL USE
  • TABLE 43: ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT FOR THE CANCER DISEASE INDICATION SEGMENT
  • TABLE 44: BIOMARKERS MARKET SIZE FOR CANCER, BY REGION, 2013-2020 ($BILLION)
  • TABLE 45: NORTH AMERICA: BIOMARKERS MARKET SIZE FOR CANCER, BY REGION, 2013-2020 ($BILLION)
  • TABLE 46: CARDIOVASCULAR DISORDER BIOMARKERS
  • TABLE 47: BIOMARKERS MARKET SIZE FOR CARDIOVASCULAR DISORDERS, BY REGION, 2013-2020 ($BILLION)
  • TABLE 48: NORTH AMERICA: BIOMARKERS MARKET SIZE FOR CARDIOVASCULAR DISORDERS, BY REGION, 2013-2020 ($BILLION)
  • TABLE 49: BIOMARKERS MARKET SIZE FOR NEUROLOGICAL DISORDERS, BY REGION, 2013-2020 ($BILLION)
  • TABLE 50: NORTH AMERICA: BIOMARKERS MARKET SIZE FOR NEUROLOGICAL DISORDERS, BY REGION, 2013-2020 ($BILLION)
  • TABLE 51: BIOMARKERS FOR IMMUNOLOGICAL DISEASES
  • TABLE 52: BIOMARKERS MARKET SIZE FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2013-2020 ($BILLION)
  • TABLE 53: NORTH AMERICA: BIOMARKERS MARKET SIZE FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2013-2020 ($BILLION)
  • TABLE 54: BIOMARKERS FOR RENAL DISORDERS
  • TABLE 55: BIOMARKERS MARKET SIZE FOR OTHER DISEASE INDICATIONS, BY REGION, 2013-2020 ($BILLION)
  • TABLE 56: NORTH AMERICA: BIOMARKERS MARKET SIZE FOR OTHER DISEASE INDICATIONS, BY REGION, 2013-2020 ($BILLION)
  • TABLE 57: BIOMARKERS MARKET SIZE, BY REGION, 2013-2020 ($BILLION)
  • TABLE 58: NORTH AMERICA: BIOMARKERS MARKET SIZE, BY COUNTRY, 2013-2020 ($BILLION)
  • TABLE 59: NORTH AMERICA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2013-2020 ($BILLION)
  • TABLE 60: NORTH AMERICA: BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION)
  • TABLE 61: NORTH AMERICA: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION)
  • TABLE 62: NORTH AMERICA: BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 ($BILLION)
  • TABLE 63: NORTH AMERICA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2013-2020 ($BILLION)
  • TABLE 64: U.S.: BIOMARKERS MARKET SIZE, BY PRODUCT, 2013-2020 ($BILLION)
  • TABLE 65: U.S.: BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION)
  • TABLE 66: U.S.: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION)
  • TABLE 67: U.S.: BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 ($BILLION)
  • TABLE 68: U.S.: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2013-2020 ($BILLION)
  • TABLE 69: CANADA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2013-2020 ($BILLION)
  • TABLE 70: CANADA: BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION)
  • TABLE 71: CANADA: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION)
  • TABLE 72: CANADA: BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 ($BILLION)
  • TABLE 73: CANADA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2013-2020 ($BILLION)
  • TABLE 74: EUROPE: BIOMARKERS MARKET SIZE, BY PRODUCT, 2013-2020 ($BILLION)
  • TABLE 75: EUROPE: BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION)
  • TABLE 76: EUROPE: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION)
  • TABLE 77: EUROPE: BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 ($BILLION)
  • TABLE 78: EUROPE: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2013-2020 ($BILLION)
  • TABLE 79: ASIA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2013-2020 ($BILLION)
  • TABLE 80: ASIA: BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION)
  • TABLE 81: ASIA: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION)
  • TABLE 82: ASIA: BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 ($BILLION)
  • TABLE 83: ASIA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2013-2020 ($BILLION)
  • TABLE 84: ROW: BIOMARKERS MARKET SIZE, BY PRODUCT, 2013-2020 ($BILLION)
  • TABLE 85: ROW: BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION)
  • TABLE 86: ROW: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2013-2020 ($BILLION)
  • TABLE 87: ROW: BIOMARKERS MARKET SIZE, BY APPLICATION, 2013-2020 ($BILLION)
  • TABLE 88: ROW: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2013-2020 ($BILLION)
  • TABLE 89: MARKET DEVELOPMENTS BETWEEN JANUARY 2012 AND MAY 2015
  • TABLE 90: ACQUISITION, 2012-2015
  • TABLE 91: AGREEMENT, COLLABORATIONS, EXPANSION, JOINT VENTURES AND PARTNERSHIPS, 2012-2015
  • TABLE 92: NEW PRODUCT AND SERVICE LAUNCHES, 2012-2015
  • TABLE 93: OTHER DEVELOPMENTS, 2012-2015

LIST OF FIGURES

  • FIGURE 1: BIOMARKERS MARKET
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 5: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: BIOMARKERS MARKET SIZE, BY PRODUCT, 2015 VS. 2020 ($BILLION)
  • FIGURE 8: BIOMARKERS MARKET SIZE, BY TYPE, 2015 VS. 2020 ($BILLION)
  • FIGURE 9: BIOMARKERS MARKET SIZE, BY APPLICATION, 2015 VS. 2020 ($BILLION)
  • FIGURE 10: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2015 VS. 2020 ($BILLION)
  • FIGURE 11: BIOMARKERS MARKET SIZE, BY REGION, 2015 VS. 2020 ($BILLION)
  • FIGURE 12: GLOBAL BIOMARKERS MARKET TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD
  • FIGURE 13: CONSUMABLES SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2015
  • FIGURE 14: ASIA TO WITNESS HIGHEST GROWTH RATE IN THE FORECAST PERIOD
  • FIGURE 15: ASIAN MARKET SHOWS LUCRATIVE GROWTH OPPORTUNITIES
  • FIGURE 16: BIOMARKERS MARKET: BY PRODUCT
  • FIGURE 17: BIOMARKERS MARKET: BY TYPE
  • FIGURE 18: BIOMARKERS MARKET: BY APPLICATION
  • FIGURE 19: BIOMARKERS MARKET: BY DISEASE INDICATION
  • FIGURE 20: BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 21: INCREASING HEALTHCARE EXPENDITURE IS THE MOST IMPORTANT DRIVER FOR THE BIOMARKERS MARKET
  • FIGURE 22: INCREASING R&D INVESTMENTS BOOSTING GROWTH IN THE BIOMARKERS MARKET
  • FIGURE 23: BIOMARKERS MARKET, BY PRODUCT
  • FIGURE 24: CONSUMABLES SEGMENT TO COMMAND THE LARGEST SHARE OF THE BIOMARKERS MARKET IN 2015
  • FIGURE 25: NORTH AMERICA WILL BE THE LARGEST REGIONAL SEGMENT OF THE CONSUMABLES MARKET IN 2015
  • FIGURE 26: ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT OF THE BIOMARKER SERVICES MARKET BETWEEN 2015 AND 2020
  • FIGURE 27: NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE BIOMARKER SOFTWARE MARKET IN 2015
  • FIGURE 28: BIOMARKERS MARKET, BY TYPE
  • FIGURE 29: SAFETY BIOMARKERS TO COMMAND THE LARGEST SHARE OF THE BIOMARKERS MARKET IN 2015
  • FIGURE 30: ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT FOR SAFETY BIOMARKERS IN THE FORECAST PERIOD
  • FIGURE 31: EFFICACY BIOMARKERS MARKET, BY TYPE
  • FIGURE 32: PREDICTIVE BIOMARKERS SEGMENT TO COMMAND THE LARGEST SHARE OF THE EFFICACY BIOMARKERS MARKET IN 2015
  • FIGURE 33: NORTH AMERICA TO BE THE LARGEST REGIONAL SEGMENT FOR EFFICACY BIOMARKERS IN 2015
  • FIGURE 34: ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT OF THE PREDICTIVE BIOMARKERS MARKET BETWEEN 2015 AND 2020
  • FIGURE 35: NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE SURROGATE BIOMARKERS MARKET IN 2015
  • FIGURE 36: ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT FOR PHARMACODYNAMIC BIOMARKERS IN THE FORECAST PERIOD
  • FIGURE 37: NORTH AMERICA TO BE THE LARGEST REGIONAL SEGMENT OF THE PROGNOSTIC BIOMARKERS MARKET IN 2015
  • FIGURE 38: ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT FOR VALIDATION BIOMARKERS BETWEEN 2015 AND 2020
  • FIGURE 39: BIOMARKERS MARKET, BY APPLICATION
  • FIGURE 40: DIAGNOSTICS DEVELOPMENT TO COMMAND THE LARGEST SHARE OF THE BIOMARKERS MARKET IN 2015
  • FIGURE 41: NORTH AMERICA IS EXPECTED TO BE THE LARGEST REGIONAL MARKET FOR DIAGNOSTICS DEVELOPMENT
  • FIGURE 42: ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT IN THE DRUG DISCOVERY AND DEVELOPMENT MARKET
  • FIGURE 43: NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE PERSONALIZED MEDICINE MARKET IN 2015
  • FIGURE 44: ASIA IS THE FASTEST-GROWING REGIONAL SEGMENT FOR DISEASE RISK ASSESSMENT
  • FIGURE 45: NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE BIOMARKERS MARKET FOR OTHER APPLICATIONS
  • FIGURE 46: BIOMARKERS MARKET, BY DISEASE INDICATION
  • FIGURE 47: CANCER WILL BE THE LARGEST DISEASE INDICATION SEGMENT OF THE BIOMARKERS MARKET IN 2015
  • FIGURE 48: NORTH AMERICA TO BE THE LARGEST REGIONAL SEGMENT FOR BIOMARKERS FOR CARDIOVASCULAR DISORDERS IN 2015
  • FIGURE 49: ASIAN BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS TO GROW AT THE HIGHEST RATE
  • FIGURE 50: NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS IN 2015
  • FIGURE 51: ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT OF THE BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS
  • FIGURE 52: GLOBAL ECONOMIC INDICATORS (2003-2012)
  • FIGURE 53: BIOMARKERS MARKET SIZE AND GROWTH RATE, BY REGION, 2015-2020
  • FIGURE 54: BIOMARKERS MARKET IN ASIA TO WITNESS HIGHEST GROWTH RATE FROM 2015 TO 2020
  • FIGURE 55: NORTH AMERICA: ECONOMIC INDICATORS (2003-2012)
  • FIGURE 56: NORTH AMERICA: MARKET SNAPSHOT
  • FIGURE 57: CONSUMABLES IS ESTIMATED TO BE THE LARGEST PRODUCT SEGMENT OF THE NORTH AMERICAN BIOMARKERS MARKET IN 2015
  • FIGURE 58: SAFETY BIOMARKERS TO COMMAND THE LARGEST SHARE OF THE NORTH AMERICAN BIOMARKERS MARKET BY 2020
  • FIGURE 59: PREDICTIVE BIOMARKERS SEGMENT WILL CONTINUE TO DOMINATE THE EFFICACY BIOMARKERS MARKET IN NORTH AMERICA
  • FIGURE 60: DIAGNOSTICS DEVELOPMENT SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICAN BIOMARKERS APPLICATIONS MARKET IN 2015
  • FIGURE 61: CANCER TO ACCOUNT FOR THE LARGEST DISEASE INDICATION SEGMENT OF THE NORTH AMERICAN BIOMARKERS MARKET IN 2015
  • FIGURE 62: U.S.: ECONOMIC INDICATORS (2003-2012)
  • FIGURE 63: CONSUMABLES TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. BIOMARKERS PRODUCTS MARKET IN 2015
  • FIGURE 64: SAFETY BIOMARKERS TO FORM THE LARGEST SEGMENT OF THE U.S. BIOMARKERS MARKET IN 2015
  • FIGURE 65: PREDICTIVE BIOMARKERS WILL CONTINUE TO DOMINATE THE EFFICACY BIOMARKERS MARKET IN THE U.S.
  • FIGURE 66: DIAGNOSTICS DEVELOPMENT TO COMMAND THE LARGEST SHARE OF THE U.S. BIOMARKERS APPLICATIONS MARKET IN 2015
  • FIGURE 67: CANCER TO FORM THE LARGEST DISEASE INDICATION SEGMENT OF THE U.S. BIOMARKERS MARKET IN 2015
  • FIGURE 68: CANADA: ECONOMIC INDICATORS (2003-2012)
  • FIGURE 69: CONSUMABLES TO ACCOUNT FOR THE LARGEST SEGMENT OF THE CANADIAN BIOMARKERS PRODUCTS MARKET IN 2015
  • FIGURE 70: SAFETY BIOMARKERS TO DOMINATE THE CANADIAN BIOMARKERS MARKET BY 2020
  • FIGURE 71: PREDICTIVE BIOMARKERS WILL CONTINUE TO DOMINATE THE CANADIAN EFFICACY BIOMARKERS MARKET
  • FIGURE 72: DIAGNOSTICS DEVELOPMENT SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE CANADIAN BIOMARKERS MARKET IN 2015
  • FIGURE 73: CANCER TO FORM THE LARGEST DISEASE INDICATION SEGMENT OF THE CANADIAN BIOMARKERS MARKET IN 2015
  • FIGURE 74: EUROPE: ECONOMIC INDICATORS (2003-2012)
  • FIGURE 75: CONSUMABLES IS ESTIMATED TO BE THE LARGEST PRODUCT SEGMENT OF THE EUROPEAN BIOMARKERS MARKET IN 2015
  • FIGURE 76: SAFETY BIOMARKERS TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPEAN BIOMARKERS MARKET IN 2015
  • FIGURE 77: PREDICTIVE BIOMARKERS TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPEAN EFFICACY BIOMARKERS MARKET IN 2015
  • FIGURE 78: DIAGNOSTICS DEVELOPMENT SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPEAN BIOMARKERS APPLICATIONS SEGMENT IN 2015
  • FIGURE 79: CANCER TO FORM THE LARGEST DISEASE INDICATION SEGMENT OF THE EUROPEAN BIOMARKERS MARKET IN 2015
  • FIGURE 80: ASIA: ECONOMIC INDICATORS (2003-2012)
  • FIGURE 81: ASIA: MARKET SNAPSHOT
  • FIGURE 82: CONSUMABLES IS ESTIMATED TO BE THE LARGEST SEGMENT OF THE ASIAN BIOMARKERS MARKET IN 2015
  • FIGURE 83: SAFETY BIOMARKERS TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIAN BIOMARKERS MARKET IN 2015
  • FIGURE 84: PREDICTIVE BIOMARKERS TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIAN EFFICACY BIOMARKERS MARKET IN 2015
  • FIGURE 85: DIAGNOSTICS DEVELOPMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIAN BIOMARKERS APPLICATIONS MARKET IN 2015
  • FIGURE 86: CANCER TO FORM THE LARGEST DISEASE INDICATION SEGMENT OF THE ASIAN BIOMARKERS MARKET IN 2015
  • FIGURE 87: REST OF THE WORLD: ECONOMIC INDICATORS (2003-2012)
  • FIGURE 88: CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ROW BIOMARKERS PRODUCTS MARKET IN 2015
  • FIGURE 89: SAFETY BIOMARKERS TO ACCOUNT FOR THE LARGEST SHARE OF THE ROW BIOMARKERS MARKET IN 2015
  • FIGURE 90: PREDICTIVE BIOMARKERS TO ACCOUNT FOR THE LARGEST SHARE OF THE ROW EFFICACY BIOMARKERS MARKET IN 2015
  • FIGURE 91: DIAGNOSTICS DEVELOPMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE ROW BIOMARKERS APPLICATIONS MARKET IN 2015
  • FIGURE 92: CANCER TO FORM THE LARGEST DISEASE INDICATION SEGMENT OF THE ROW BIOMARKERS MARKET IN 2015
  • FIGURE 93: KEY DEVELOPMENTS WITHIN THE OVERALL BIOMARKERS MARKET, 2012 TO 2015
  • FIGURE 94: BIOMARKERS MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2014
  • FIGURE 95: FINANCIAL PERFORMANCE OF LEADING MARKET PLAYERS
  • FIGURE 96: COMPANY SNAPSHOT: QIAGEN N.V.
  • FIGURE 97: COMPANY SNAPSHOT: PERKINELMER, INC.
  • FIGURE 98: COMPANY SNAPSHOT: MERCK & CO, INC.
  • FIGURE 99: COMPANY SNAPSHOT: BIO-RAD LABORATORIES, INC.
  • FIGURE 100: COMPANY SNAPSHOT: ENZO BIOCHEM, INC.
  • FIGURE 101: COMPANY SNAPSHOT: EKF DIAGNOSTICS HOLDINGS, INC.
Back to Top